Motivation: A subset (20,000 people/yr in the US) of total knee arthroplasty patients develop an infection that can be extremely challenging to diagnose and treat. In fact, these infections have worse mortality rates (~20%) than common cancers (i.e., breast cancer, prostate cancer, etc.). We are developing injectable materials that can sense joint infection, and inform the patient about the status of their joint from their own home, providing enhanced information for this critical population.
Patent: A provisional patent has been filed on this technology.